RXi raises $16.2 million

RXi Pharmaceuticals Corp. (NASDAQ:RXII) raised $16.2 million through the sale of 2.7 million units at $6 in a registered direct offering. Each unit comprises a share and a six-year warrant to purchase 0.2 shares, with each whole warrant exercisable at $6. Rodman was placement agent. RXi is developing rxRNA compounds, which are highly active and potent RNA interference (RNAi) compounds that have increased resistance to nucleases. ...